BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Linden Announces Closing of New $375 Million Investment Fund


6/25/2010 11:15:59 AM

CHICAGO, June 25 /PRNewswire/ -- Linden LLC, a Chicago-based healthcare focused private equity firm, today announced that it has successfully completed fundraising for Linden Capital Partners II ("LCP II"), which closed with $375 million of committed capital and exceeded its target of $300 million and initial cap of $350 million.

Linden's second fund continues the strategy from its first fund, executed through industry specialization in healthcare and life science, a focus on building and maintaining corporate relationships, and integrating Operating Partners in investment decisions and management. Linden received strong support from its institutional investors, 100% of whom reinvested in LCP II. In addition, the firm attracted new global LPs, state pension plans, foundations, funds of funds, and family offices.

Linden Founder and Partner, Eric Larson, said, "We are pleased to have exceeded our fundraising target in a very demanding environment. This was definitely a team effort, involving the entire Linden organization as well as the talented managers at our portfolio companies." Brian Miller, Linden Founder and Partner, continued, "It is the consistent ability of our portfolio companies' executive teams to improve the performance of the companies we own that continues to reward our investors and attract new ones, and we thank them for their important role in this successful outcome."

Linden Founder and Partner, Tony Davis, said, "We have worked very hard to deliver returns to our investors, and we are extremely pleased to have surpassed our fundraising expectations with strong support from our existing limited partners. We also want to welcome our highly regarded new group of investors to our global investor base. With their collective support, Linden looks forward to the continuous improvement of our approach to creating value in the companies we acquire."

Linden this year was named as Best New Firm by Buyouts magazine, which cited "impressive" exits and the firm's pursuit of "small healthcare companies that are poised to benefit from market trends."

LCP II follows Linden's successful first fund of $200 million, established in 2006. Park Hill Group served as placement agent for LCP II, and Kirkland & Ellis served as legal counsel.

About Linden Capital Partners

Linden is a Chicago-based private equity firm focused exclusively on leveraged buyouts in the healthcare and life science industries. Linden's strategy is based upon four elements: i) specialization on middle market healthcare and life science companies, ii) integrated private equity and operating expertise, iii) customized value creation programs for each portfolio company, and iv) strategic relationships with large corporations. Linden's portfolio includes BarrierSafe Solutions International, Behavioral Centers of America, CORPAK MedSystems, Drayer Physical Therapy, Focused Health Solutions, Hycor Biomedical, and Ranir. For additional information, please visit www.lindenllc.com.

Contact:

Chris Tofalli


914-834-4334


ctofalli@lindenllc.com



SOURCE Linden LLC



Read at BioSpace.com

Linden
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES